AI assistant
PCAS — Interim / Quarterly Report 2014
Apr 22, 2014
1590_iss_2014-04-22_9f611f97-a249-4604-8903-14a2ccfefd64.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
Longjumeau, April 22, 2014
Net sales
| (in thousands of euros) | 2013 | 2014 | % change |
|---|---|---|---|
| Sales as of 31 March | 43 033 | 42 053 | -2,3% |
| including Pharmaceutical Synthesis | 26 677 | 27 117 | 1,6% |
| including Fine Speciality Chemicals | 16 356 | 14 936 | -8,7% |
Consolidated net sales for the PCAS Group are down 2.3% in the first quarter of 2014 compared to the same period for the previous year.
Pharmaceutical synthesis
Pharmaceutical Synthesis activities are continuing to develop in 2014, up 1.6% compared to the first quarter of 2013.
Fine Specialty Chemicals
Fine Specialty Chemicals net sales are down 8.7% compared to the first quarter of 2013, but up 23% compared to the last quarter of 2013.
Next meeting: Shareholders' meeting April 23, 2014, 10.00 a.m. in Longjumeau
About PCAS:
Founded in 1962, PCAS is an international fine and specialty chemicals group (165 million € net sales in 2013) that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability. PCAS also develops ranges of proprietary products based on intellectual property.